| 17 déc. 2025 Déposé le 19 déc. 2025 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) Common Stock | Cédé (D) | 148 153 | 11,00 | 1 629 683 Calculé : actions × prix par action. Valeur exacte 1629683.00. | 0 | Indirecte (I) See Footnote | Non | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| Ouvrir le dépôt 0001104659-25-123156 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 19 déc. 2025 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) Titre dérivé: Prefunded Warrants — sous-jacent Common Stock (433 962) — prix d’exercice 0.0001 | Cédé (D) | 433 962 | 10,999 | 4 773 148,038 Calculé : actions × prix par action. Valeur exacte 4773148.038. | 0 | Indirecte (I) See Footnote | Non | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| Ouvrir le dépôt 0001104659-25-123156 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 19 déc. 2025 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) Titre dérivé: Series A Common Stock Purchase Warrants — sous-jacent Common Stock (117 019) — prix d’exercice 8.16 | Cédé (D) | 117 019 | 4,71 | 551 159,49 Calculé : actions × prix par action. Valeur exacte 551159.49. | 0 | Indirecte (I) See Footnote | Non | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| Ouvrir le dépôt 0001104659-25-123156 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 19 déc. 2025 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) Titre dérivé: Series C Common Stock Purchase Warrants — sous-jacent Common Stock (117 019) — prix d’exercice 8.16 | Cédé (D) | 117 019 | 4,71 | 551 159,49 Calculé : actions × prix par action. Valeur exacte 551159.49. | 0 | Indirecte (I) See Footnote | Non | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| Ouvrir le dépôt 0001104659-25-123156 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 19 déc. 2025 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) Titre dérivé: Amended Series A Common Stock Purchase Warrants — sous-jacent Common Stock (158 531) — prix d’exercice 0.01 | Cédé (D) | 158 531 | 10,99 | 1 742 255,69 Calculé : actions × prix par action. Valeur exacte 1742255.69. | 0 | Indirecte (I) See Footnote | Non | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| Ouvrir le dépôt 0001104659-25-123156 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 19 déc. 2025 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) Titre dérivé: Amended Series C Common Stock Purchase Warrants — sous-jacent Common Stock (250 627) — prix d’exercice 0.01 | Cédé (D) | 250 627 | 10,99 | 2 754 390,73 Calculé : actions × prix par action. Valeur exacte 2754390.73. | 0 | Indirecte (I) See Footnote | Non | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| Ouvrir le dépôt 0001104659-25-123156 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 218) — prix d’exercice 5.41 | Cédé (D) | 1 218 | — | — | 0 | Directe (D) | Non | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322642 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (5 833) — prix d’exercice 4.45 | Cédé (D) | 5 833 | — | — | 0 | Directe (D) | Non | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322642 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 218) — prix d’exercice 3.453 | Cédé (D) | 1 218 | — | — | 0 | Directe (D) | Non | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322642 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 479) — prix d’exercice 5.41 | Cédé (D) | 1 479 | — | — | 0 | Directe (D) | Non | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322643 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (8 750) — prix d’exercice 4.45 | Cédé (D) | 8 750 | — | — | 0 | Directe (D) | Non | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322643 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 291) — prix d’exercice 3.453 | Cédé (D) | 1 291 | — | — | 0 | Directe (D) | Non | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322643 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 187) — prix d’exercice 5.41 | Cédé (D) | 1 187 | — | — | 0 | Directe (D) | Non | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322641 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (5 833) — prix d’exercice 4.45 | Cédé (D) | 5 833 | — | — | 0 | Directe (D) | Non | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322641 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 187) — prix d’exercice 3.453 | Cédé (D) | 1 187 | — | — | 0 | Directe (D) | Non | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322641 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 250) — prix d’exercice 5.41 | Cédé (D) | 1 250 | — | — | 0 | Directe (D) | Non | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322638 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (5 833) — prix d’exercice 4.45 | Cédé (D) | 5 833 | — | — | 0 | Directe (D) | Non | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322638 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 250) — prix d’exercice 3.453 | Cédé (D) | 1 250 | — | — | 0 | Directe (D) | Non | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322638 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 218) — prix d’exercice 5.41 | Cédé (D) | 1 218 | — | — | 0 | Directe (D) | Non | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322639 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (5 833) — prix d’exercice 4.45 | Cédé (D) | 5 833 | — | — | 0 | Directe (D) | Non | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322639 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 187) — prix d’exercice 3.453 | Cédé (D) | 1 187 | — | — | 0 | Directe (D) | Non | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322639 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | Smeal Benjamin C. Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (5 833) — prix d’exercice 5.51 | Cédé (D) | 5 833 | — | — | 0 | Directe (D) | Non | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322645 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | Smeal Benjamin C. Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 125) — prix d’exercice 3.453 | Cédé (D) | 1 125 | — | — | 0 | Directe (D) | Non | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322645 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | CARLSON MARILYN R. Officer: Chief Medical Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (17 291) — prix d’exercice 5.27 | Cédé (D) | 17 291 | — | — | 0 | Directe (D) | Non | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322644 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | CARLSON MARILYN R. Officer: Chief Medical Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (11 000) — prix d’exercice 4.45 | Cédé (D) | 11 000 | — | — | 0 | Directe (D) | Non | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322644 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (64 840) — prix d’exercice 5.27 | Cédé (D) | 64 840 | — | — | 0 | Directe (D) | Non | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322637 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (70 000) — prix d’exercice 4.45 | Cédé (D) | 70 000 | — | — | 0 | Directe (D) | Non | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322637 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | Kowieski Mark Officer: Chief Financial Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (17 291) — prix d’exercice 5.27 | Cédé (D) | 17 291 | — | — | 0 | Directe (D) | Non | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322640 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | Kowieski Mark Officer: Chief Financial Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (13 000) — prix d’exercice 4.45 | Cédé (D) | 13 000 | — | — | 0 | Directe (D) | Non | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322640 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | PYSZCZYMUKA GREG Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (5 833) — prix d’exercice 5.26 | Cédé (D) | 5 833 | — | — | 0 | Directe (D) | Non | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322646 Lu dans le XML du dépôt Contester cette ligne |
| 17 déc. 2025 Déposé le 17 déc. 2025 | PYSZCZYMUKA GREG Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 155) — prix d’exercice 3.453 | Cédé (D) | 1 155 | — | — | 0 | Directe (D) | Non | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| Ouvrir le dépôt 0001193125-25-322646 Lu dans le XML du dépôt Contester cette ligne |
| 16 déc. 2025 Déposé le 17 déc. 2025 | Hill Malcolm R Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Cédé (D) | 133 | — | — | 0 | Directe (D) | Non | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| Ouvrir le dépôt 0001193125-25-322642 Lu dans le XML du dépôt Contester cette ligne |
| 16 déc. 2025 Déposé le 17 déc. 2025 | GARNER CAM L Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Cédé (D) | 2 330 | — | — | 0 | Indirecte (I) By Garner Investments, L.L.C. | Non | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| Ouvrir le dépôt 0001193125-25-322643 Lu dans le XML du dépôt Contester cette ligne |
| 16 déc. 2025 Déposé le 17 déc. 2025 | Brady Todd C Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Cédé (D) | 27 | — | — | 0 | Directe (D) | Non | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| Ouvrir le dépôt 0001193125-25-322639 Lu dans le XML du dépôt Contester cette ligne |
| 16 déc. 2025 Déposé le 17 déc. 2025 | CARLSON MARILYN R. Officer: Chief Medical Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Cédé (D) | 360 | — | — | 0 | Directe (D) | Non | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| Ouvrir le dépôt 0001193125-25-322644 Lu dans le XML du dépôt Contester cette ligne |
| 16 déc. 2025 Déposé le 17 déc. 2025 | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Cédé (D) | 15 509 | — | — | 0 | Directe (D) | Non | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| Ouvrir le dépôt 0001193125-25-322637 Lu dans le XML du dépôt Contester cette ligne |
| 16 déc. 2025 Déposé le 17 déc. 2025 | Kowieski Mark Officer: Chief Financial Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Cédé (D) | 11 815 | — | — | 0 | Directe (D) | Non | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| Ouvrir le dépôt 0001193125-25-322640 Lu dans le XML du dépôt Contester cette ligne |